Biotech IPOs on the Chinese mainland have dried up since June 2023 due to regulatory tightening, but Hong Kong is still open to listings of pre-revenue ventures and has seen its first offering of this year.

The UK firm's shareholders have not approved plans to acquire Bioasis, a decision that puts Midatech in a tricky situation as its cash will run out by mid-March.

The board has resigned at the crisis-hit Norwegian firm after shareholders voted against a reverse merger with APIM Therapeutics.

Five months after its lead drug Betalutin failed for follicular lymphoma, Nordic Nanovector has secured its future by teaming up with Trondheim-based APIM and gained access to its mid-stage investigational therapy for ovarian cancer, sarcoma and glioblastoma.